Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

[New therapeutic approaches in glioblastomas].

Carpentier AF.

Rev Neurol (Paris). 2005 Mar;161(3):267-73. Review. French.

PMID:
15800447
2.

[New therapeutic approaches in glioblastomas].

Le Guilloux J, Carpentier AF.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):554-9. doi: 10.1016/j.neurol.2008.03.017. Review. French.

PMID:
18565354
3.

[New therapeutic approaches in glioblastomas].

Carpentier AF.

Bull Cancer. 2005 Apr;92(4):355-9. Review. French.

4.

Novel targeted radiosensitisers in cancer treatment.

Zaidi SH, Huddart RA, Harrington KJ.

Curr Drug Discov Technol. 2009 Jun;6(2):103-34. Review.

PMID:
19519337
5.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
6.

Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.

Newton HB.

Curr Opin Investig Drugs. 2007 Dec;8(12):1009-21. Review.

PMID:
18058572
7.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
8.

Combining molecular therapeutics with radiotherapy for head and neck cancer.

Riesterer O, Milas L, Ang KK.

J Surg Oncol. 2008 Jun 15;97(8):708-11. doi: 10.1002/jso.21011. Review.

PMID:
18493923
9.

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.

Ronellenfitsch MW, Steinbach JP, Wick W.

Target Oncol. 2010 Sep;5(3):183-91. doi: 10.1007/s11523-010-0154-5. Review.

PMID:
20853178
10.

Targeted molecular therapy of malignant gliomas.

Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY.

Curr Neurol Neurosci Rep. 2005 May;5(3):186-97. Review.

PMID:
15865884
11.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
12.

Changing boundaries in the treatment of malignant gliomas.

Brandes AA, Basso U, Pasetto LM.

Expert Rev Anticancer Ther. 2001 Oct;1(3):357-70. Review.

PMID:
12113103
13.

Targeting growth factors and angiogenesis; using small molecules in malignancy.

Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H.

Cancer Metastasis Rev. 2006 Jun;25(2):279-92. Review.

PMID:
16770540
14.

New approaches in metastatic melanoma: biological and molecular targeted therapies.

Lejeune FJ, Rimoldi D, Speiser D.

Expert Rev Anticancer Ther. 2007 May;7(5):701-13. Review.

PMID:
17492933
15.

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.

Tortora G, Ciardiello F, Gasparini G.

Nat Clin Pract Oncol. 2008 Sep;5(9):521-30. doi: 10.1038/ncponc1161. Review.

PMID:
18594498
16.
17.

[New therapies for non-small cell lung cancer].

Ostoros G, Kovács G, Szondy K, Döme B.

Orv Hetil. 2005 May 22;146(21):1135-41. Review. Hungarian.

PMID:
15991677
18.

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Faivre S, Djelloul S, Raymond E.

Semin Oncol. 2006 Aug;33(4):407-20. Review.

PMID:
16890796
19.

[New strategies to interfere with radiation response: "biomodulation" of radiation therapy].

Deutsch E, Kaliski A, Maggiorella L, Bourhis J.

Cancer Radiother. 2005 Mar;9(2):69-76. Review. French.

PMID:
15820434
20.

Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.

Ramos FJ, Macarulla T, Capdevila J, Elez E, Tabernero J.

Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S52-7. doi: 10.3816/CCC.2008.s.008. Review.

PMID:
19064407

Supplemental Content

Support Center